Correction to: Scientific Reports https://doi.org/10.1038/s41598-019-44874-0, published online 10 June 2019
This Article contains a typographical error in the Materials and Methods section under subheading ‘Immunohistochemistry and scoring’ where,
“Formalin-fixed, paraffin-embedded tumor sections or tumor microarrays were processed and stained with anti-CLDN18.2 mAb, followed by detection with EnVision HRP-labeled polymer anti-rabbit second Ab (Dako K4002) based on standard protocol.”
should read:
“Formalin-fixed, paraffin-embedded tumor sections or tumor microarrays were processed and stained with anti-CLDN18.2 mAb, followed by detection with EnVision HRP-labeled polymer anti-mouse second Ab (Dako K4001) based on standard protocol.”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhu, G., Foletti, D., Liu, X. et al. Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Sci Rep 9, 16735 (2019). https://doi.org/10.1038/s41598-019-53130-4
Published:
DOI: https://doi.org/10.1038/s41598-019-53130-4
This article is cited by
-
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Molecular Cancer (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
